The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
Open accessAbstract
BACKGROUND: Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. METHODS: We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected incidence within 21 days after the first dose and 30 days after the second dose, independent of certainty of diagnosis; and by calculating the rate ratio 30 days after the second dose as compared with unvaccinated persons. RESULTS: Among 304 persons with symptoms of myocarditis, 21 had received an alternative diagnosis. Of the remaining 283 cases, 142 occurred after receipt of the BNT162b2 vaccine; of these cases, 136 diagnoses were definitive or probable. The clinical presentation was judged to be mild in 129 recipients (95%); one fulminant case was fatal. The overall risk difference between the first and second doses was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46). As compared with the expected incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6.40) and was highest after the second dose in male recipients between the ages of 16 and 19 years (13.60; 95% CI, 9.30 to 19.20). The rate ratio 30 days after the second vaccine dose in fully vaccinated recipients, as compared with unvaccinated persons, was 2.35 (95% CI, 1.10 to 5.02); the rate ratio was again highest in male recipients between the ages of 16 and 19 years (8.96; 95% CI, 4.50 to 17.83), with a ratio of 1 in 6637. CONCLUSIONS: The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the vaccine was associated with increased risk of myocarditis in Israeli participants, reaching a rate of approximately 3 events per 100,000 persons.398–400”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [399]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citationSafety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Mei, R., Raschi, E., Forcesi, E., Diemberger, I., Ponti, F. D., & Poluzzi, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.054 · Cited by 84
Surveillance Guidelines for Smallpox Vaccine (vaccinia) Adverse Reactions
Casey, C., Vellozzi, C. J., Mootrey, G. T., Chapman, L. E., McCauley, M. M., Roper, M. H., Damon, I. K., & Swerdlow, D. L. (2006) · PsycEXTRA Dataset · doi:10.1037/e506942006-001 · Cited by 58
Flagged first, then by citations
Research works printed but not linked: 1
- Sahai H Khurshid A. Statistics in epidemiology: methods techniques and applications. Boca Raton FL: CRC Press 1996.
Cited by
Sorted by citations
Oster, M. E., Shay, D. K., Su, J. R., Gee, J. M., Creech, C. B., Broder, K. R., Edwards, K. M., Soslow, J. H., Dendy, J. M., Schlaudecker, E. P., et al. (2022) · JAMA · doi:10.1001/jama.2021.24110 · Cited by 686
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar‐Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01630-0 · Cited by 647
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Covid-19 Vaccines — Immunity, Variants, Boosters
Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 451
Gluckman, T. J., Bhave, N. M., Allen, L. A., Chung, E. H., Spatz, E. S., Ammirati, E., Baggish, A. L., Bozkurt, B., Cornwell, W. K., Harmon, K. G., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.003 · Cited by 431
Diagnosis and Treatment of Acute Myocarditis: A Review
Ammirati, E., & Moslehi, J. J. (2023) · JAMA · doi:10.1001/jama.2023.3371 · Cited by 379
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
Husby, A., Hansen, J. V., Fosbøl, E. L., Thiesson, E. M., Madsen, M., Thomsen, R. W., Sørensen, H. T., Andersen, M. T., Wohlfahrt, J., Gislason, G., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068665 · Cited by 273
Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. (2021) · Vaccines · doi:10.3390/vaccines9121490 · Cited by 275
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
Heymans, S., & Cooper, L. T. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00662-w · Cited by 244
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar‐Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059970 · Cited by 247
Basso, C. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2114478 · Cited by 241
SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents
Karlstad, Ø., Hovi, P., Husby, A., Härkänen, T., Selmer, R. M., Pihlström, N., Hansen, J. V., Nohynek, H., Gunnes, N., Sundström, A., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0583 · Cited by 221
Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225
Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., Thacker, D., Elias, M. D., Li, J. S., Toro-Salazar, O. H., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056583 · Cited by 183
Wong, H., Hu, M., Zhou, C. K., Lloyd, P. C., Amend, K. L., Beachler, D. C., Secora, A. M., McMahill‐Walraven, C. N., Lu, Y., Wu, Y., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00791-7 · Cited by 169
Ling, R. R., Ramanathan, K. R., Tan, F. L., Tai, B. C., Somani, J., Fisher, D. A., & MacLaren, G. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00059-5 · Cited by 168
Heidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., Tschöpe, C., Kelle, S., Poland, G. A., Frustaci, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2669 · Cited by 159
Buchan, S. A., Seo, C. Y., Johnson, C., Alley, S., Kwong, J. C., Nasreen, S., Calzavara, A., Lu, D., Harris, T. M., Yu, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.18505 · Cited by 157
Pillay, J., Bialy, L., Gaudet, L., Wingert, A., Mackie, A. S., Paterson, D. I., & Hartling, L. (2022) · BMJ · doi:10.1136/bmj-2021-069445 · Cited by 149
Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine
Lai, F. T. T., Li, X., Peng, K., Huang, L., Ip, P., Tong, X., Chui, C. S. L., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-3700 · Cited by 143
Cardiac involvement in the long-term implications of COVID-19
Satterfield, B. A., Bhatt, D. L., & Gersh, B. J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00631-3 · Cited by 138
Should children be vaccinated against COVID-19?
Zimmermann, P., Pittet, L. F., Finn, A. H. R., Pollard, A. J., & Curtis, N. C. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323040 · Cited by 131
Impact of COVID-19 on Cardiovascular Disease
Vosko, I., Zirlik, A., & Bugger, H. (2023) · Viruses · doi:10.3390/v15020508 · Cited by 139
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz‐Foumani, R., Kolahi, A., Singh, K., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2318 · Cited by 120
JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis
Nagai, T., Inomata, T., Kohno, T., Sato, T., Tada, A., Kubo, T., Nakamura, K., Oyama‐Manabe, N., Ikeda, Y., Fujino, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-22-0696 · Cited by 120
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
Vu, S. L., Bertrand, M., Jabagi, M.-J., Botton, J., Drouin, J., Baricault, B., Weill, A., Dray‐Spira, R., & Zureik, M. (2022) · Nature Communications · doi:10.1038/s41467-022-31401-5 · Cited by 117
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
Green, M. S., Peer, V., Magid, A., HaGani, N., Anis, E., & Nitzan, D. (2022) · Vaccines · doi:10.3390/vaccines10020233 · Cited by 109
Self-citationThe Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury
Siripanthong, B., Asatryan, B., Hanff, T. C., Chatha, S., Khanji, M. Y., Ricci, F., Muser, D., Ferrari, V. A., Nazarian, S., Santangeli, P., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.011 · Cited by 102
Viral Myocarditis: Classification, Diagnosis, and Clinical Implications
Sozzi, F. B., Gherbesi, E., Faggiano, A., Gnan, E., Maruccio, A., Schiavone, M., Iacuzio, L., & Carugo, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.908663 · Cited by 109
Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis
Voleti, N., Reddy, S. P., & Ssentongo, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951314 · Cited by 98
Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
Mansanguan, S., Charunwatthana, P., Piyaphanee, W., Dechkhajorn, W., Poolcharoen, A., & Mansanguan, C. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7080196 · Cited by 83
IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination
Thurner, L., Kessel, C., Fadle, N., Regitz, E., Seidel, F., Kindermann, I., Lohse, S., Kos, I., Tschöpe, C., Kheiroddin, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2205667 · Cited by 83
Self-citationKwan, A. C., Ebinger, J. E., Wei, J., Le, C. N., Oft, J. R., Zabner, R., Teodorescu, D. L., Botting, P. G., Navarrette, J., Ouyang, D., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00177-8 · Cited by 80
Herrera, D., & Campos, G. D. L. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07262-0 · Cited by 78
Khan, N. A., Al-Thani, H. A. S., & El-Menyar, A. A. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102246 · Cited by 74
Chen, L., Chua, G. T., Lu, L., Chan, B. P.-C., Wong, J. S. C., Chow, C. C. K., Yu, T.-C., Leung, A. S. Y., Lam, S.-Y., Wong, T.-W., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2035195 · Cited by 71
Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview
Shiravi, A. A., Ardekani, A., Sheikhbahaei, E., & Heshmat‐Ghahdarijani, K. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00248-0 · Cited by 73
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
Schwab, C., Domke, L. M., Hartmann, L., Stenzinger, A., Longerich, T., & Schirmacher, P. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02129-5 · Cited by 76
Myocarditis associated with COVID-19 vaccination
Buoninfante, A., Andeweg, A. C., Genov, G., & Cavaleri, M. (2024) · npj Vaccines · doi:10.1038/s41541-024-00893-1 · Cited by 81
Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination
Goddard, K., Lewis, N., FIREMAN, B. H., Weintraub, E., Shimabukuro, T. T., Zerbo, O., Boyce, T. G., Oster, M. E., Hanson, K. E., Donahue, J. G., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.007 · Cited by 70
BNT162b2 Vaccine‐Associated Myo/Pericarditis in Adolescents: A Stratified Risk‐Benefit Analysis
Krug, A., Stevenson, J., & Høeg, T. B. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13759 · Cited by 69
Lane, S., Yeomans, A., & Shakir, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059223 · Cited by 71
Cardiovascular Magnetic Resonance in Myocarditis
Polte, C. L., Bobbio, E., Bollano, E., Bergh, N., Polte, C., Himmelman, J., Lagerstrand, K. M., & Gao, S. A. (2022) · Diagnostics · doi:10.3390/diagnostics12020399 · Cited by 75
Ouldali, N., Bagheri, H., Salvo, F., Antona, D., Pariente, A., Leblanc, C., Tebacher, M., Micallef, J., Lévy, C., Cohen, R., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100393 · Cited by 69
Bardosh, K., Krug, A., Jamrozik, E., Lemmens, T., Keshavjee, S. A., Prasad, V. K., Makary, M., Baral, S., & Høeg, T. B. (2022) · Journal of Medical Ethics · doi:10.1136/jme-2022-108449 · Cited by 75
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 72
Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
Mevorach, D., Anis, E., Cedar, N., Hasin, T., Bromberg, M., Goldberg, L., Parnasa, E., Dichtiar, R., Hershkovitz, Y., Ash, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2116999 · Cited by 61
Self-citationAutopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose
Gill, J. R., Tashjian, R., & Duncanson, E. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0435-sa · Cited by 62
Sessa, F., Salerno, M., Esposito, M., Nunno, N. R. D., Zamboni, P., & Pomara, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245876 · Cited by 60
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 56
Lai, F. T. T., Chua, G. T., Chan, E. W. W., Huang, L., Kwan, M. Y. W., Ma, T., Qin, X. S., Chui, C. S. L., Li, X., Wan, E. Y. F., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2050952 · Cited by 57
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
Ammirati, E., Bizzi, E., Veronese, G., Groh, M., Heyning, C. M. V. D., Lehtonen, J. Y. A., de Chambrun, M. P., Cereda, A. F., Picchi, C., Trotta, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.838564 · Cited by 61
Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
Lai, F. T. T., Chan, E. W. W., Huang, L., Cheung, C. L., Chui, C. S. L., Li, X., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., Yiu, K. H., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.049 · Cited by 55
Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
Choe, Y. J., Yi, S., Hwang, I., Kim, J., Park, Y.-J., Cho, E., Jo, M., Lee, H., & Choi, E. H. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.044 · Cited by 50
Tsilingiris, D., Vallianou, N. G., Karampela, Ι., Liu, J., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100159 · Cited by 51
Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?
Cosentino, M., & Marino, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810881 · Cited by 56
Gao, J., Feng, L., Li, Y., Lowe, S., Guo, Z., Bentley, R., Xie, C., Wu, B., Xie, P., Xia, W., et al. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.09.002 · Cited by 60
Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., Eden, G. L., Tee, Y. C., Benson, S. C., Masavuli, M. G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100971 · Cited by 52
Mouliou, D. S., & Dardiotis, E. (2022) · Diagnostics · doi:10.3390/diagnostics12071555 · Cited by 49
COVID ‐19 vaccine induced myocarditis in young males: A systematic review
Knudsen, B., & Prasad, V. K. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13947 · Cited by 48
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Acevedo‐Whitehouse, K. A., & Bruno, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111015 · Cited by 56
Mahroum, N., Lavine, N., Ohayon, A., Seida, R., Alwani, A., Alrais, M., Zoubi, M., & Bragazzi, N. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872683 · Cited by 50
Fatima, M., Cheema, H. A., Khan, M. H. A., Shahid, H., Ali, M. S., Hassan, U., Murad, M. W., Rehman, M. A. U., & Farooq, H. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103486 · Cited by 47
Wong, C. K. H., Lau, K. T. K., Xiong, X., Au, I. C. H., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Li, X., Chan, E. W., Gao, L., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004018 · Cited by 45
Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065687 · Cited by 44
COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events
Giannotta, G., Murrone, A., & Giannotta, N. (2023) · Vaccines · doi:10.3390/vaccines11040747 · Cited by 45
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox, J. R., Lucas, C. G. D. O., Yildirim, I. B., Dai, Y., Wang, E. Y., Monteiro, V. S., Lord, S. M., Carlin, J. S., Kita, M., Buckner, J. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36686-8 · Cited by 46
Ferreira, V. M., Plein, S., Wong, T. C., Tao, Q., Raisi‐Estabragh, Z., Jain, S., Han, Y., Ojha, V., Bluemke, D. A., Hanneman, K. A., et al. (2023) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-023-00933-0 · Cited by 42
Li, L., Honda-Okubo, Y., Baldwin, J., Bowen, R., Bielefeldt-Ohmann, H., & Petrovsky, N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.041 · Cited by 38
Stowe, J., Miller, E., Andrews, N. J., & Whitaker, H. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004245 · Cited by 46
Tomkins‐Netzer, O., Sar, S., Barnett‐Griness, O., Friedman, B., Shyriaieva, H., & Saliba, W. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.05.015 · Cited by 43
Self-citationAnalysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Straus, W., Urdaneta, V., Esposito, D. B., Mansi, J. A., Sanz Rodriguez, C., Burton, P., & Vega, J. M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac446 · Cited by 41
Vaccination-Associated Myocarditis and Myocardial Injury
Altman, N. L., Berning, A. A., Mann, S., Quaife, R. A., Gill, E. A., Auerbach, S. R., Campbell, T., & Bristow, M. R. (2023) · Circulation Research · doi:10.1161/circresaha.122.321881 · Cited by 42
Stein, M., Ashkenazi‐Hoffnung, L., Greenberg, D., Dalal, I., Livni, G., Chapnick, G., Stein‐Zamir, C., Ashkenazi, S., Sagie, L. H., & Grossman, Z. (2022) · Vaccines · doi:10.3390/vaccines10010081 · Cited by 41
Husby, A., Gulseth, H. L., Hovi, P., Hansen, J. V., Pihlström, N., Gunnes, N., Härkänen, T., Dahl, J., Karlstad, Ø., Heliö, T. M., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000373 · Cited by 41
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
Copland, E., Patone, M., Saatci, D., Handunnetthi, L., Hirst, J. A., Hunt, D. P. J., Mills, N. L., Moss, P. A. H., Sheikh, A., Coupland, C. A. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47745-z · Cited by 40
Myocarditis in Athletes Recovering from COVID-19: A Systematic Review and Meta-Analysis
Modica, G., Bianco, M., Sollazzo, F., Murro, E. D., Monti, R., Cammarano, M., Morra, L., Nifosì, F. M., Gervasi, S. F., Gravina, E. M., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074279 · Cited by 40
Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults
Yasuhara, J., Masuda, K., Aikawa, T., Shirasu, T., Takagi, H., Lee, S., & Kuno, T. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.4768 · Cited by 39
A Case of Multisystem Inflammatory Syndrome in a 12-Year-old Male After COVID-19 mRNA Vaccine
Yalçınkaya, R., Öz, F. N., Polat, M., Uçan, B., Teke, T. A., Kaman, A., Özdem, S., Şen, Z. S., Cinni, R. G., & Tanir, G. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003432 · Cited by 36
The pathological maelstrom of COVID-19 and cardiovascular disease
Giacca, M., & Shah, A. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00029-5 · Cited by 37
Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination
Kornowski, R., & Witberg, G. (2022) · Open Heart · doi:10.1136/openhrt-2021-001957 · Cited by 35
COVID-19 mRNA vaccination and myocarditis or pericarditis
Husby, A., & Køber, L. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00842-x · Cited by 34
Innate and adaptive immunity in acute myocarditis
Golino, M., Harding, D., Buono, M. G. D., Fanti, S., MOHIDDIN, S. A., Toldo, S. A., Smyth, J. W., Sanna, T., Marelli‐Berg, F. M., & Abbate, A. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131901 · Cited by 41
Wan, E. Y. F., Wang, Y., Chui, C. S. L., Mok, A. H. Y., Xu, W., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00125-8 · Cited by 36
Information systems for vaccine safety surveillance
Buttery, J. P., & Clothier, H. J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2100173 · Cited by 34
Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies
Paknahad, M. H., Yancheshmeh, F. B., & Soleimani, A. (2023) · Heart & Lung · doi:10.1016/j.hrtlng.2023.02.003 · Cited by 34
Myocarditis associated with COVID-19 and its vaccines - a systematic review
Rout, A., Suri, S. S., Vorla, M., & Kalra, D. K. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.10.004 · Cited by 38
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Niesen, M. J. M., Pawlowski, C., O’Horo, J. C., Challener, D. W., Silvert, E., Donadio, G., Lenehan, P. J., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7038 · Cited by 33
Thuluva, S., Paradkar, V. M., Gunneri, S., Yerroju, V., Mogulla, R. R., Suneetha, P. V., Turaga, K., Kyasani, M., Manoharan, S. K., Adabala, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.045 · Cited by 31
Cardiovascular Assessment up to One Year After COVID-19 Vaccine–Associated Myocarditis
Yu, C. K.-M., Tsao, S. S. L., Ng, C. W.-K., Chua, G. T., Chan, K.-L., Shi, J. J., Chan, Y. Y.-T., Ip, P., Kwan, M. Y. W., & Cheung, Y. (2023) · Circulation · doi:10.1161/circulationaha.123.064772 · Cited by 33
Ilonze, O. J., & Guglin, M. E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10243-9 · Cited by 32
Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31
Shibata, S., Kobayashi, K., Tanaka, M., Asayama, K., Yamamoto, E., Nakagami, H., Hoshide, S., Kishi, T., Matsumoto, C., Mogi, M., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01134-5 · Cited by 36
Receipt of mRNA Vaccine against Covid-19 and Myocarditis
Caforio, A. L. P. (2021) · New England Journal of Medicine · doi:10.1056/nejme2116493 · Cited by 33
Overview of U.S. COVID-19 vaccine safety surveillance systems
Gee, J. M., Shimabukuro, T. T., Su, J. R., Shay, D. K., Ryan, M. A. K., Basavaraju, S. V., Broder, K. R., Clark, M. P. A., Creech, C. B., Cunningham, F. E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.065 · Cited by 36
Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland
Babicki, M., & Mastalerz–Migas, A. (2022) · Vaccines · doi:10.3390/vaccines10010068 · Cited by 31
Safety monitoring of COVID-19 vaccines in Japan
Yamaguchi, T., Iwagami, M., Ishiguro, C., Fujii, D., Yamamoto, N., Narisawa, M., Tsuboi, T., Umeda, H., Kinoshita, N., Iguchi, T., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100442 · Cited by 31
Naveed, Z., Li, J., Wilton, J., Spencer, M., Naus, M., García, H. A. V., Kwong, J. C., Rose, C., Otterstatter, M. C., & Janjua, N. Z. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.799 · Cited by 32
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
Laurini, G. S., Montanaro, N., Broccoli, M., Bonaldo, G., & Motola, D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.054 · Cited by 31
Metadata
- Authors
- Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M. S., Keinan-Boker, L., & Alroy-Preis, S.
- Affiliations
- Bar-Ilan University (IL)
- From the Department of Internal Medicine B, Division of Immunology–Rheumatology, and Wohl Institute for Translational Medicine (D.M.) and the Departments of Cardiology (R.A., O.A.), Pathology (K. Meir), and Radiology (D.C.), Hadassah Medical Center, Braun School of Public Health (E.A.), Jesselson Integrated Heart Center, Shaare Zedek Medical Center (T.H., N.L.), and the Department of Family Medicine (I.M.), Faculty of Medicine, Hebrew University of Jerusalem, the Divisions of Epidemiology (E.A., N.C., E.J.H., E.N.), Patient Safety (S.O.-C., D.A.), and Medicine (I.L.), Israeli Ministry of Health (M.B., R. Dichtiar, D.N., Y.H., Y.L., L.K.-B., S.A.-P.), and Clalit Health Services (E.N., I.M.), Jerusalem, Israel Center for Disease Control, and Azrieli Faculty of Medicine, Bar-Ilan University (O.A.), Ramat Gan, the Department of Epidemiology and Preventive Medicine, School of Public Health (M.B., K. Muhsen), and Tel Aviv Sourasky Medical Center (R.B.-A.), Tel Aviv University, Tel Aviv, Ben Gurion University of ...
- Corresponding author
- Alroy-Preis, Sharon
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-02
- Volume
- 385
- Issue
- 23
- Pages
- 2140-2149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8531987
- OpenAlex
- W3204791524
- Cited by
- 599
- References
- 7
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 84 · 2023: 125 · 2022: 280 · 2021: 41
- FWCI
- 88.83
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- myocarditis, BNT162b2 mRNA vaccine, COVID-19 vaccination, vaccine adverse events, incidence, standardized incidence ratio, risk difference, second vaccine dose, young men, Israel, active surveillance, adverse event reporting, vaccine safety surveillance, COVID-19 mortality, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- COVID-19, BNT162 Vaccine, Adolescent, Adult, Echocardiography, Female, Hospitalization, Humans, Israel, Male, Middle Aged, Myocarditis, Retrospective Studies, Comorbidity, Incidence, Age Distribution, Sex Distribution, Kaplan-Meier Estimate, Young Adult, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
